A61K 31/551
Having two nitrogen atoms
Official title: having two nitrogen atoms, e.g. dilazep
A61K31/551 (Having two nitrogen atoms) appears on 2,844 US grants and 5,460 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,844
- Published applications
- 5,460
- Assignees
- 1,819
- Inventors
- 10,576
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 11 | 0 |
| 1997 | 20 | 0 |
| 1998 | 40 | 0 |
| 1999 | 35 | 0 |
| 2000 | 24 | 0 |
| 2001 | 27 | 8 |
| 2002 | 35 | 64 |
| 2003 | 49 | 111 |
| 2004 | 57 | 176 |
| 2005 | 36 | 142 |
| 2006 | 72 | 193 |
| 2007 | 31 | 142 |
| 2008 | 44 | 124 |
| 2009 | 49 | 134 |
| 2010 | 52 | 153 |
| 2011 | 53 | 128 |
| 2012 | 67 | 156 |
| 2013 | 96 | 183 |
| 2014 | 128 | 257 |
| 2015 | 170 | 301 |
| 2016 | 171 | 281 |
| 2017 | 193 | 340 |
| 2018 | 207 | 270 |
| 2019 | 205 | 300 |
| 2020 | 161 | 303 |
| 2021 | 176 | 281 |
| 2022 | 133 | 293 |
| 2023 | 135 | 284 |
| 2024 | 142 | 308 |
| 2025 | 119 | 292 |
| 2026 | 91 | 236 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Use of multikinase inhibitor6 Oct 2026US 12,751,957 B2Transthera Sciences (Nanjing), Inc.
- Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof6 Oct 2026US 12,753,166 B2Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Sirt6 activators6 Oct 2026US 12,753,180 B2Board of Regents, The University of Texas System
- Treatment of inflammatory diseases of the central nervous system29 Sep 2026US 12,746,245 B2Palmaya Pty Ltd
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors8 Oct 2026US 2026/0306505 A1BioAxone BioSciences, Inc.
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and serine beta-lactamase inhibitor8 Oct 2026US 2026/0306526 A1Adjutec Pharma AS
- Crystalline forms of evenamide8 Oct 2026US 2026/0308115 A1Newron Pharmaceuticals S.p.A.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Abuse-proofed dosage system297US 7,776,314 B2GrüNenthal GmbH · 2010